Loading
A phase 2 trial of WSD0922-FU Tablets, Dose level A in non-small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT06868485 by Wayshine Biopharm, Inc., with 40 participants planned, started 2025-08-18 and due to reach its primary completion in 2027-09-30. Interventions recorded: WSD0922-FU Tablets, Dose level A and WSD0922-FU Tablets, Dose level B.
Shares Wayshine Biopharm, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Wayshine Biopharm, Osimertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.